OmniAb names Amechi Nwachuku as Chief Operating Officer
The appointment took effect July 13, 2026, with a base salary of $445,000 and stock options for 800,000 shares.
OmniAb, Inc. disclosed in an 8-K filing that Amechi Nwachuku was appointed as the Chief Operating Officer of OmniAb, Inc., effective July 13, 2026.1
Nwachuku, 51, has worked in life sciences for more than two decades across tools, biotechnology, diagnostics, pharmaceuticals, medical devices, and consumer health.1 He most recently served as Vice President, Global Commercial, Genetic Sciences at Thermo Fisher Scientific from May 2024 to April 2025.1 Before that, he was Senior Vice President, Global Commercial at SCIEX, a Danaher Corporation company, from August 2021 to June 2023, and held a commercial management role covering Eastern Europe and the Middle East at Beckman Coulter Diagnostics, another Danaher unit, from January 2019 to August 2021.1 From August 2016 to December 2018 he was Regional Vice President for the Johnson & Johnson Diabetes Care Companies1, and he held several leadership positions at Bayer from 2006 to 2016.1 He holds an MBA from the MIT Sloan School of Management and a B.S. in Chemical Engineering from MIT.1
Under his offer letter, Nwachuku's starting base salary is $445,000 a year, and he can earn a target bonus of 45% of that salary, prorated for 2026.1 He also received a $20,000 signing bonus.1 Effective August 1, 2026, the company granted him options to buy 800,000 shares, vesting over four years with 12.5% vesting after six months and the rest monthly thereafter.1
Nwachuku will also participate in OmniAb's Severance Plan, which covers involuntary termination without cause,1 and he has signed a change in control severance agreement providing benefits if he is terminated without cause or resigns for good reason within 24 months of a change in control.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.